

TABLE OF CONTENTS

Sr. No.	Title	Page No.
Chapter 1.	Computer Aided Drug Design: An Overview	1-35
1.1	Abstract	1
1.2	Introduction	1
1.2.1	Receptor theory	3
1.3	Molecular Modeling and Computational Chemistry	5
1.4	Quantum Mechanics and Molecular Mechanics	6
1.5	Force Fields	7
1.6	Energy-Minimizing Procedures	7
1.6.1	Steepest Descent Method	8
1.6.2	Conjugate Gradient Method	8
1.7	Computer-aided Drug Design	9
1.7.1	Structure-Based Drug Design	10
1.7.2	Ligand-Based Drug Design	18
1.8	Database Searching	24
1.9	De Novo Drug Design	24
1.10	Aim of the Present Work	25
1.11	References	27
Chapter 2.	Introduction to antifungal drugs	36-63
2.1	Abstract	36
2.2	Introduction	36
2.2.1	Introduction of fungi	38
2.2.2	Characteristics and Classification of Fungi	39
2.2.3	Fungi and Human Disease	41
2.3	Potential Targets for Antifungal Drug Development	42
2.4	General Antifungal Agents	48
2.5	References	62

Chapter 3.	3D- QSAR of N- substituted Imidazoles as antifungal agents	64-86
3.1	Abstract	64
3.2	Introduction	64
3.3	Material and Methods	65
3.3.1	Biological data	65
3.3.2	Computational details.	69
3.3.2.1	CoMFA study	69
3.3.2.2	Alignment rules	69
3.2.2.3	Generation of CoMFA fields	70
3.2.2.4	Partial Least Square (PLS) analysis	71
3.2.2.5	Predictive r^2 value (r^2_{pred})	73
3.2.2.6	Model building using GFA	73
3.2.2.7	Conformational sampling	73
3.2.2.8	Calculation of descriptors	73
3.2.2.9	Generation of QSAR models	75
3.3	Results	75
3.3.1	CoMFA	75
3.4	GFA	78
3.5	Discussion	79
3.5.1	CoMFA	79
3.5.2	GFA	83
3.6	Conclusions	83
3.7	References	84
Chapter 4.	Pharmacophore modeling and atom-based 3D-QSAR studies of antifungal benzofurans	87-105
4.1	Abstract	87
4.2	Introduction	87
4.3	Materials and Methods	89
4.3.1	Dataset	89
4.3.2	Ligand Preparation	92
4.3.4	Generation of Common Pharmacophore Hypothesis (CPH)	93

4.3.4	Scoring Pharmacophore Hypothesis	93
4.3.5	Building QSAR models	94
4.3.6	Validation of Pharmacophore Model	94
4.4	Results and Discussion	95
4.4.1	Pharmacophore generation and 3D-QSAR model analysis	95
4.6	Conclusion	102
4.7	References	103
Chapter 5.	Insight into the structural requirement of cytochrome P450 lanosterol 14α- demethylase inhibitors as potential antifungal agents based on 3D-QSAR and molecular docking	106-144
5.1	Abstract	106
5.2	Introduction	106
5.3	Material and methods	108
5.3.1	Datasets	108
5.3.2	Alignment and Molecular modeling	115
5.3.3	CoMFA and CoMSIA fields Generation	117
5.3.4	Partial least square analysis and model validation	117
5.3.5	Predictive correlation coefficient (r^2_{pred})	118
5.3.6	Docking	119
5.4.	Results and discussion	119
5.4.1	CoMFA studies	119
5.4.2	CoMSIA studies	121
5.4.3	3D-QSAR visualization	124
5.4.3.1	CoMFA	124
5.4.3.2	CoMSIA	125
5.4.3.3	Analysis of CoMFA and CoMSIA contour map	126
5.4.3.3.1	CoMFA	126
5.4.3.3.2	CoMSIA	129
5.4.4	Docking	136
5.5	Conclusion	139

5.6	References	140
Chapter 6.	Synthesis, Antifungal activity, QSAR, Molecular Docking and <i>in silico</i> ADMET Studies of Triazol-4-ylamine Derivatives	145-220
6.1	Abstract	145
6.2	Introduction	145
6.3	Review of Literature	146
6.4	Need of Work	159
6.5	Aim and Objectives of the Present Work	159
6.6	Material and Methods	160
6.6.1	Chemistry	160
6.6.2	Synthesis Scheme of Compounds	160
6.6.2.1	Synthesis of 3,5-Dimethyl-[1,2,4]triazol-4-ylamine	160
6.6.2.2	Procedure for synthesis of 3,5-Dimethyl-[1,2,4]triazol-4-ylamine	161
6.6.2.3	synthesis of 3,5-Dimethyl-[1,2,4]triazol-4-ylamine derivatives	161
6.6.2.4	General Procedure for synthesis of 3,5-dimethyl-[1,2,4]triazol-4-ylamine derivatives	161
6.6.3	Pharmacological Screening	161
6.6.3.1	Primary screening	161
6.6.3.2	Secondary Screening	162
6.6.4	QSAR Studies	163
6.6.4.1	Software	163
6.6.4.2	Generation of QSAR Models	163
6.6.5	Molecular Docking	164
6.6.6	Prediction of ADMET properties for the designed derivatives	165
6.6.7	Bioactivity score prediction	165
6.6.8	Molecular properties prediction	166
6.7	Result and Discussion	166
6.7.1	Characterization Studies	166
6.7.2	Antifungal activity	192

6.7.3	QSAR Studies	194
6.7.3.1	Chemical Data	194
6.7.3.2	Software	194
6.7.3.3	Calculation of descriptors	195
6.7.3.4	Multiple Linear Regression analysis	199
6.7.4	Molecular Docking	201
6.7.5	Molecular properties prediction	207
6.7.6	Prediction of ADMET properties for the synthesized compounds	208
6.7.7	Bioactivity score prediction	212
6.8	Conclusion	213
6.9	References	214
Chapter 7.	Summary of Present Research Work	221-228
Chapter 8.	Scope for Future Work	229-231
Appendix I	List of Publications	232
Appendix II	Errata	

LIST OF TABLES

Table No.	Title	Page No.
1.1	Example of Marketed Drugs Involving use of Structure based Drug Design	11
2.1	Taxonomic Classes of Fungi	41
2.2	Three-dimensional characterization of antifungal targets determined by different methods	48
2.3	Biochemical basis of azole resistance	56
3.1	Structures and activities of the molecules in the training and test sets	69
3.2	Summary of CoMFA results	71
3.3	Results of analysis with cross validation for 2 and 5 groups and randomized biological activities for RMS fit	72
3.4	Descriptors used in the GFA analysis	74
3.5	QSAR equations generated using genetic function approximation for the training set of fifty molecules	78
4.1	Structure and activities of the molecules in the training (1–24) and test (25–29) sets	90
4.2	Best Pharmacophore hypothesis according to scoring values	99
4.3	Statistic parameters for best pharmacophore hypothesis	100
5.1	Antifungal activities of triazole derivatives (1-33) used for training and test sets	109
5.2	Statistical parameter by using PLS analysis for CoMFA	120
5.3	Statistical parameter by using PLS analysis for CoMSIA	120
5.4	Experimental, predicted pIC ₈₀ and residual values of training set compounds by CoMFA and CoMSIA analysis	122
5.5	Experimental, predicted pIC ₈₀ values and residual values of test set compound by CoMFA and CoMSIA analysis	123
6.1	Physicochemical characterization data of synthesized compounds VMSP 1-16	166
6.2	IR spectrum data of 3,5-Dimethyl-[1,2,4]triazol-4-ylamine (VMSP1)	169
6.3	¹ H-NMR spectrum data of 3,5-Dimethyl-[1,2,4]triazol-4-ylamine.(VMSP 1)	170
6.4	IR spectrum data of <i>N</i> -(3,5-Dimethyl-[1,2,4]triazol-4-yl)-benzene-1,4-diamine (VMSP 2)	171
6.5	¹ H-NMR (DMSO) spectrum data of <i>N</i> -(3,5-Dimethyl-[1,2,4]triazol-4-yl)-benzene-1,4-diamine (VMSP 2)	172
6.6	IR spectrum data of <i>N</i> -(3,5-Dimethyl-[1,2,4]triazol-4-yl)-benzene-1,3-diamine. (VMSP 3)	173
6.7	IR spectrum data of (3,5-Dimethyl-[1,2,4]triazol-4-yl)-phenyl-amine. (VMSP 4)	174

6.8	IR spectrum data of (3,5-Dimethyl-[1,2,4]triazol-4-yl)-(2-nitrophenyl)-amine.(VMSP 5)	175
6.9	IR spectrum data of 2-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-phenol. (VMSP 6)	176
6.10	¹ H-NMR spectrum data of 2-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-phenol.(VMSP 6)	177
6.11	IR spectrum data of 4-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-benzoic acid. (VMSP 7)	178
6.12	¹ H-NMR spectrum data of 4-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-benzoic acid. (VMSP7)	179
6.13	IR spectrum data of 2-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-benzoic acid. (VMSP 8)	180
6.14	IR spectrum data of 3-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-benzoic acid. (VMSP 9)	181
6.15	IR spectrum of 4-(3,5-Dimethyl[1,2,4]triazol-4-ylamino)-phenol.(VMSP 10)	182
6.16	IR spectrum data of Benzothiazol-2-yl-(3,5-dimethyl-[1,2,4]triazol-4-yl)-amine.(VMSP11)	183
6.17	IR spectrum data of (1H-Benzotrizol-5-yl)-(3,5-dimethyl-[1,2,4]triazol-4-yl)-amine. (VMSP 12)	184
6.18	IR spectrum data of (3,5-Dimethyl-[1,2,4]triazol-4-yl)-(4-nitrophenyl)-amine. (VMSP 13)	185
6.19	IR spectrum of (3,5-Dimethyl-[1,2,4]triazol-4-yl)- <i>p</i> -tolyl-amine. (VMSP 14)	186
6.20	IR spectrum of 3,5-Dimethyl-[1,2,4]triazol-4-yl)-(2-methyl-5-nitrophenyl)-amine. (VMSP 15)	187
6.21	IR spectrum data of 2-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-4-nitro-benzoic acid. (VMSP 16)	188
6.22	<i>In vitro</i> antifungal activity of <i>N</i> -Substituted (3,5-dimethyl-[1,2,4]triazole-4-yl)benzene-4-amine derivatives (Zone of Inhibition).	192
6.23	<i>In vitro</i> antifungal activity of <i>N</i> -Substituted (3,5-Dimethyl-[1,2,4]triazole-4-yl)benzen-4-amine derivatives MIC against <i>Candida albicans</i> .	193
6.24	Biological activity of <i>N</i> -substituted (3,5 Dimethyl-[1,2,4]triazol-4-yl)-benzene-4-amine derivatives	195
6.25	Descriptor used for QSAR study	198
6.26	QSAR models for the series of <i>N</i> -substituted (3,5 Dimethyl-[1,2,4]triazol-4-yl)-benzene-4-amine derivatives	199
6.27	The data of observed and calculated biological activity	200
6.28	Predicted Lipinski's rule of five for standards and designed Triazole analogues	207
6.29a	Predicted biological permeability of standards and synthesized triazole analogues.	209

6.29b	Predicted biological permeability of standards and and synthesized triazole analogues.	210
6.29c	Predicted biological permeability of standards and and synthesized triazole analogues.	211
6.30	Predicted biological activity of standards and synthesized triazole analogues	212

LIST OF FIGURES

Figure No.	Title	Page No.
1.1	Stages in the drug discovery process	3
1.2	Virtual drug discovery process	3
1.3	CADD in drug discovery/design pipeline	10
1.4	Steps in homology model building process	13
1.5	3D-QSAR and virtual screening workflow	21
1.6	Overview of the workflow of computer aided drug design	25
2.1	Potential targets for antifungal drug development.	43
2.2	Sites of action of some antifungal agents	44
2.3	Key events in antifungal drug development	49
3.1	Molecule 07 with atoms used for superimposition are marked in red.	70
3.2	Graph of observed activity versus predicted activities of training set molecules from multi fit alignment of CoMFA analysis, activity expressed as $-\log(\text{MIC}_{\text{compd}}/\text{MIC}_{\text{bifonazole}})$.	76
3.3	Graph of observed activity versus predicted activities of test set molecules from multi fit alignment of CoMFA analysis, activity expressed as $-\log(\text{MIC}_{\text{compd}}/\text{MIC}_{\text{bifonazole}})$.	77
3.4	Graph of observed activity versus predicted activities of test set molecules from GFA analysis, activity expressed as $-\log(\text{MIC}_{\text{compd}}/\text{MIC}_{\text{bifonazole}})$.	79
3.5	CoMFA steric STDEV* contour plots from the atom based fit. Sterically favored areas are represented by green polyhedra. Sterically unfavorable areas are represented by yellow polyhedra. The active molecule 07 is shown in capped-sticks.	80
3.6	CoMFA electrostatic STDEV*COEFF contour plots from atom based fit. Positive charge favored areas are represented by blue polyhedra. Negative charge favored areas are represented by red polyhedra. The active molecule 07 is shown in capped-sticks.	81
4.1	Pharmacophore hypothesis and distance between pharmacophoric sites, all distances are in A^0 unit.	96
4.2	Pharmacophore hypothesis AAPRR.5605 aligned on the all training set ligands	97
4.3	Pharmacophore hypothesis AAPRR.5605 aligned on the all test set ligands	97
4.4	Correlation graph of Experimental versus predicted pIC_{50} of training (a) and test sets (b)	98
4.5	Visual representation of atom-based 3D-QSAR model on most active ligand 23	101
4.6	Visual representation of atom-based 3D-QSAR model on least active ligand 22	101

5.1	For development of CoMFA and CoMSIA models fragment utilized as a common structure for alignment of dataset.	116
5.2	For CoMFA and CoMSIA study 1-33 aligned compounds	116
5.3	Graph of actual and predicted pIC ₃₀ value for training set by CoMFA and CoMSIA analysis.	123
5.4	Graph of actual and predicted pIC ₃₀ values for test set by CoMFA and CoMSIA analysis.	124
5.5	Most potent compound 8 distributed into (A), (B) and (C) regions.	125
5.6	Steric contour maps (a,c) and electrostatic contour maps (b, d) generated by comparative molecular field analysis (CoMFA) for the most active compound 8(a, b) and the less active compound 28(c,d), respectively.	127-129
5.7	Comparative molecular similarity indices analysis (CoMSIA) for most active compound 8(a) Steric map (green, bulky group desirable; yellow, bulky group not desirable), (b) electrostatic map contour map (blue, electropositive group desirable; red, electronegative group desirable), (c) hydrophobic map (yellow, hydrophobic group desirable; white, hydrophilic group desirable), (d) donor map (cyan, donor group desirable; purple, donor group undesirable and (e) acceptor map (magenta, acceptor group desirable; red, acceptor group undesirable).	130-133
5.8	Comparative molecular similarity indices analysis (CoMSIA) for least active compound 28(a) Steric map (green, bulky group desirable; yellow, bulky group not desirable), (b) electrostatic map contour map (blue, electropositive group desirable; red, electronegative group desirable), (c) hydrophobic map (yellow, hydrophobic group desirable; white, hydrophilic group desirable), (d) donor map (cyan, donor group desirable; purple, donor group undesirable and (e) acceptor map (magenta, acceptor group desirable; red, acceptor group undesirable).	133-136
5.9	Most active compound 8 docked with CYP51.	137
5.10	2D view most active compound 8 docked with the active site of CYP51.	137
5.11	Inactive compound 28 docked with CYP51.	138
5.12	2D view of inactive compound 28 docked with active site of CYP51.	138
6.1	IR spectrum of 3,5-Dimethyl-[1,2,4]triazol-4-ylamine (VMSP 1)	169
6.2	¹ H-NMR spectrum of 3,5-Dimethyl-[1,2,4]triazol-4-ylamine.(VMSP 1)	170
6.3	IR spectrum of <i>N</i> -(3,5-Dimethyl-[1,2,4]triazol-4-yl)-benzene-1,4-diamine. (VMSP 2)	171
6.4	¹ H-NMR spectrum of <i>N</i> -(3,5-Dimethyl-[1,2,4]triazol-4-yl)-benzene-1,4-diamine. (VMSP 2)	172
6.5	IR spectrum of <i>N</i> -(3,5-Dimethyl-[1,2,4]triazol-4-yl)-benzene-1,3-diamine. (VMSP 3)	173
6.6	IR spectrum of (3,5-Dimethyl-[1,2,4]triazol-4-yl)-phenyl-amine. (VMSP 4)	174
6.7	IR spectrum of (3,5-Dimethyl-[1,2,4]triazol-4-yl)-(2-nitro-phenyl)-amine.(VMSP 5)	175

6.8	IR spectrum of 2-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-phenol.(VMSP 6)	176
6.9	¹ H-NMR spectrum of 2-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-phenol.(VMSP 6)	177
6.10	IR spectrum of 4-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-benzoic acid. (VMSP 7)	178
6.11	¹ H-NMR spectrum of 4-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-benzoic acid. (VMSP 7)	179
6.12	IR spectrum of 2-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-benzoic acid. (VMSP 8)	180
6.13	IR spectrum of 3-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-benzoic acid. (VMSP 9)	181
6.14	IR spectrum of 4-(3,5-Dimethyl[1,2,4]triazol-4-ylamino)-phenol. (VMSP 10)	182
6.15	IR spectrum of Benzothiazol-2-yl-(3,5-dimethyl-[1,2,4]triazol-4-yl)-amine.(VMSP 11)	183
6.16	IR spectrum of (1H-Benzotrizol-5-yl)-(3,5-dimethyl-[1,2,4]triazol-4-yl)-amine.(VMSP 12)	184
6.17	IR spectrum of (3,5-Dimethyl-[1,2,4]triazol-4-yl)-(4-nitro-phenyl)-amine. (VMSP 13)	185
6.18	IR spectrum of (3,5-Dimethyl-[1,2,4]triazol-4-yl)- <i>p</i> -tolyl-amine. (VMSP 14)	186
6.19	IR spectrum of 3,5-Dimethyl-[1,2,4]triazol-4-yl)-(2-methyl-5-nitro-phenyl)-amine. (VMSP 15)	187
6.20	IR spectrum of 2-(3,5-Dimethyl-[1,2,4]triazol-4-ylamino)-4-nitro-benzoic acid. (VMSP 16)	188
6.21	Photographic representation of antifungal activity	194
6.22	Graph of observed Vs. Predicted activity.	201
6.23	3D view of ocking interaction of most active compound (A) VMSP 7	202
6.24	2D view of docking interaction of most active compound (A) VMSP 7	202
6.25	3D view of ocking interaction of most active compound (B) VMSP 12	203
6.26	2D view of docking interaction of most active compound (B) VMSP 12	203
6.27	3D view of ocking interaction of most active compound (C) VMSP 13	204
6.28	2D view of docking interaction of most active compound (C) VMSP 13	204
6.29	3D view of ocking interaction of most active compound (D) VMSP 16	205
6.30	2D view of docking interaction of most active compound (D) VMSP 16	205
6.31	Docking interaction of most active compound (A) VMSP 12	206
6.32	Docking interaction of most active compound (B) VMSP 16	206

LIST OF ABBREVIATIONS

2D	Two-dimensional
3D	Three-dimensional
4D	Four-dimensional
5D	Five-dimensional
6D	Six-dimensional
ADMET	Absorption, Distribution, Metabolism, Excretion, and Toxicity
ARG	Arginine
BA	Biological Activity
CADD	Computer Aided Drug Design
CPH	Common Pharmacophore Hypothesis
CoMFA	Comparative Molecular Field Analysis
CoMSIA	Comparative Molecular Similarity Indices Analysis
CYP51	Cytochrome P450 lanosterol 14 α -demethylase
DMSO	Dimethyl sulphoxide
DDE	Dipole and Dipole energy
GFA	Genetic Function Approximation
Glide	Grid-based Ligand Docking with Energetics
Glide SP	Glide single precision docking
Glide XP	Glide extra precision docking
¹ H-NMR	Proton Nuclear Magnetic Resonance
HOMO	Highest Occupied Molecular Orbital
IR	Infrared Spectra
IC ₅₀	Half maximal inhibitory concentration
IUPAC	International Union of Pure and Applied Chemistry
LBDD	Ligand Based Drug Design
LOO	Leave one out method
LHO	Leave Half Out
LOF	Lack of fit
LUMO	Lowest Unoccupied Molecular Orbital
MET	Methionine
MLR	Multiple linear regression
MIC	Minimum Inhibitory Concentration
m.p.	Melting Point
MR	Molar Refractivity

NCEs	New Chemical Entities
Nmt	N -myristoyltransferase
ONC	Optimum number of components
OPLS	Optimized Potential for Liquid Simulation
PDB	Protein data bank
PHASE	Pharmacophore Alignment and Scoring Engine
PHE	Phenylalanine
PLS	Partial Least Square Analysis
q^2	Cross-validated correlation coefficient by leave one out method
QSAR	Quantitative structure-activity relationship
r_{bs}^2	Average r^2 from a bootstrapping
r_{ncv}^2	Non-cross-validated correlation coefficient
r_{cv}^2	Cross-validated correlation coefficient
r_{pred}^2	Predicted correlation coefficient
RMSD	Root mean square deviation
SAR	Structure-activity relationship
SBDD	Structure Based Drug Design
SD	Standard deviation
SEE	Standard Error of Estimate
SEP	Standard Error of Prediction
SER	Serine
TLC	Thin Layer Chromatography
TYR	Tyrosine
VDW	Van Der Waals